In cancer biology, the Hippo signaling has been shown to be genetically deregulated in a small subset of cancers such as mesothelioma with NF2 or LATS kinases mutations13 or hemangioendotheliomas characterized by translocations involving YAP or TAZ14,15. This evidence concerns the gene NF2 and hemangioendothelioma.